C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.
about
An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situTargeting the hepatocyte growth factor-cMET axis in cancer therapyAn overview of the c-MET signaling pathwayLRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergyMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerc-Met as a Target for Personalized TherapyMET deregulation in breast cancerTargeting RTK Signaling Pathways in CancerPotent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model.The clinical and functional significance of c-Met in breast cancer: a reviewPrognostic significance of c-Met in breast cancer: a meta-analysis of 6010 casesMultiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancerHepatocyte growth factor-like protein is a positive regulator of early mammary gland ductal morphogenesisDetection of hepatocyte growth factor (HGF) ligand-c-MET receptor activation in formalin-fixed paraffin embedded specimens by a novel proximity assayMet receptor tyrosine kinase signals through a cortactin-Gab1 scaffold complex, to mediate invadopodiaMet and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cellsMet-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells.Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surfaceQuantitative analysis of three-dimensional human mammary epithelial tissue architecture reveals a role for tenascin-C in regulating c-met function.Blood vessel endothelium-directed tumor cell streaming in breast tumors requires the HGF/C-Met signaling pathway.Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles.Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancerIn vitro and in vivo effects of suppressor of cytokine signalling 7 knockdown in breast cancer: the influence on cellular response to hepatocyte growth factor.c-MET protects breast cancer cells from apoptosis induced by sodium butyrate.Overexpression of c-Met increases the tumor invasion of human prostate LNCaP cancer cells in vitro and in vivoThe Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in CancerThe Met oncogene and basal-like breast cancer: another culprit to watch out for?A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings.New radiotracers for imaging of vascular targets in angiogenesis-related diseases.Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patientsDual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.KAP1 promotes proliferation and metastatic progression of breast cancer cellsIn vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met.The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response-Biological and Clinical AspectsDual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.Design and synthesis of 3,3'-biscoumarin-based c-Met inhibitors.Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit.Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma.Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors
P2860
Q21195234-B0E16E31-B0BD-4A77-B80B-D411704822F7Q24606259-2B54007B-6AD9-4D15-B452-6CD76FFF75F4Q24633986-04D50006-868C-430D-BB3C-C31E7CC4AC19Q24681561-7A9F136B-5922-4031-8109-531E0970B8E5Q26772969-68E17146-8C1B-4119-A200-FF4A59422A7EQ26775483-036C0758-688D-47E3-9BEA-099AB5EBEABDQ26781054-150EA948-4821-4B83-A6C2-6D8B0895444EQ26781278-198E25E6-691F-48DE-833A-3D04AC0103ADQ27853074-BF550767-46B2-44CF-8A10-ED35213D7427Q28081415-50EC141E-8FAB-4BCC-9C1C-64613EB3FAE7Q28087523-1EB74E03-11B0-416E-9F83-4CC2F4D544F3Q28478514-248E6B14-A80A-4C6A-B4FF-EFC30E5B56F6Q28593437-4F55ECE6-5909-4620-8D63-563540227710Q28743359-1EE9086E-27CB-45BC-AEBC-F251B594572EQ30010161-D58863FE-D4CF-457C-8726-0748A1BE5D3FQ30415408-7D2B98B3-231D-44FB-AF0D-B0445F038645Q30446159-3F225EF8-5255-4818-9FC3-64E77670FE11Q33585541-167C92BD-FCD1-45E2-BD10-F0387F683EFDQ33597170-D661413E-CB09-4FE5-A2D4-12199BD3F4C3Q33665092-2F912715-FC73-49C6-B442-7ED8D2670C6AQ33737789-F2488E79-6DE0-4B13-A15B-93F23BE36CFAQ33880064-866050B1-E351-4980-A901-5AE9C668E331Q33886974-B8412575-0D2D-4F8B-8332-26EB59D4DCC3Q34064613-1C9B39D2-514D-4273-A521-9937263B6AA3Q34131128-88267B01-7CFB-4989-B32F-CD5B4F2061C8Q34141440-4B766C41-2D7A-4C2F-8B9F-BB4FE4B3D895Q34141913-465EBD23-F88D-4C42-88D4-49F4B02260CCQ34173500-E76EC8E5-A03A-4DE1-9774-9DC7B5EB189FQ34185858-4890A7E2-4056-46B8-A686-653C52FBDE6BQ34216877-14300745-A944-4505-B59C-46528A9D1BB6Q34483478-F9140899-A840-4F55-AC0B-39FE8826C753Q34537725-ABF96C48-339C-4A8D-86FF-7518DEC3A28EQ34979737-4E9D2C3B-5193-4EF1-8C65-615DFC6815EAQ35070072-9026F286-D72D-4E63-9DB9-10347105185DQ35078950-0CB3B963-DD82-4CB6-AE06-A76CA561AE65Q35110418-2BC3A84B-B372-4EDB-81F1-85916ECCCE32Q35159738-4DF21072-E3B5-4A12-A955-29517138D5D1Q35222611-BED58563-0049-4084-ACF2-405F8A120B98Q35944671-C5E2D788-66DE-4053-BF59-8764167862DDQ35967197-2241BD25-D47A-4C09-B4F8-0563DF2C81C0
P2860
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
C-Met overexpression in node-p ...... tcome independent of Her2/neu.
@en
C-Met overexpression in node-p ...... tcome independent of Her2/neu.
@nl
type
label
C-Met overexpression in node-p ...... tcome independent of Her2/neu.
@en
C-Met overexpression in node-p ...... tcome independent of Her2/neu.
@nl
prefLabel
C-Met overexpression in node-p ...... tcome independent of Her2/neu.
@en
C-Met overexpression in node-p ...... tcome independent of Her2/neu.
@nl
P2093
P356
P1476
C-Met overexpression in node-p ...... tcome independent of Her2/neu.
@en
P2093
Anita Welk
Beatrice Knudsen
Dieter Prechtel
George F Vande Woude
Georgia Salanti
James H Resau
Katja Gauger
Kristina Lindemann
Nadia Harbeck
Thomas Richter
P304
P356
10.1002/IJC.20598
P577
2005-02-01T00:00:00Z